03.06.2020 | Letter to the Editor
Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease
Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2020
Einloggen, um Zugang zu erhaltenExcerpt
-
Rivaroxaban does not have FDA approval for use in non-valvular atrial fibrillation in patients with ESRD.
-
There has been increased off-label use of rivaroxaban in this population.
-
We present a case of hemorrhagic pericardial tamponade with rivaroxaban use in a patient with NVAF and ESRD.
-
We recommend a thorough risk-benefit analysis before the choice of anticoagulant in this patient population.